Urinary incontinence is among the most common and least discussed consequences of the menopausal transition. Studies place prevalence in postmenopausal women between 45% and 63%, making it more common than hot flashes in this population.[1] Many women do not raise it with clinicians, either from embarrassment or an assumption that nothing can be done.

Understanding the two main types of incontinence is prerequisite to understanding why treatments differ, and why well-intentioned approaches sometimes make things worse.

Two Types, Two Mechanisms

Stress urinary incontinence (SUI) is leaking triggered by increased intra-abdominal pressure: coughing, sneezing, laughing, lifting, or exercise. It happens when the urethral sphincter cannot resist the pressure spike. SUI is more common in younger women and is often linked to pelvic floor weakness following childbirth.

Urge urinary incontinence (UUI) is leaking associated with a sudden, intense urge that cannot be deferred. It may occur with little physical trigger: the sound of running water, putting a key in the door, or simply walking toward a bathroom. UUI reflects overactivity of the detrusor muscle (the bladder wall), which contracts before the bladder is full.

Before menopause, SUI predominates. After menopause, UUI and mixed incontinence become the dominant pattern.[1] This shift has a hormonal explanation.

How Estrogen Withdrawal Drives Urge Incontinence

Estrogen receptors are distributed throughout the lower urinary tract: in the urethra, the bladder trigone, and the pelvic floor musculature.[2] Estrogen supports the elasticity and vascularity of urethral tissue, sphincter function, and the sensitivity threshold of the detrusor muscle.

When estrogen declines, the urethral mucosa thins, sphincter function weakens, and the detrusor becomes more sensitive and prone to involuntary contractions.[2] The result is a bladder that signals fullness early and reacts strongly to minor stimuli, driving urgency and frequency.

The same tissue thinning that causes vaginal dryness (genitourinary syndrome of menopause, GSM) extends to the urethra and bladder base. These structures are anatomically and hormonally connected, which is why treating GSM often has secondary benefits for urinary symptoms.

The Systemic HRT Paradox

A counterintuitive finding from the Women's Health Initiative trial: systemic (oral) HRT was associated with statistically significant worsening of urinary incontinence and increased incidence of new incontinence (both stress and urge types) compared to placebo.[3]

This appears contradictory given the estrogen mechanism described above. The proposed explanation is that oral estrogen, through first-pass hepatic metabolism, may affect collagen synthesis in ways that differ from local tissue effects. Whatever the mechanism, the clinical implication is clear: systemic HRT should not be used to treat urinary incontinence, and women with pre-existing incontinence who start systemic HRT should know their symptoms may worsen.

The picture with local (vaginal) estrogen is different. Vaginal estrogen acts directly on urethral and bladder tissue with minimal systemic absorption, and evidence shows benefit for urgency and frequency specifically.[4] Randomised trials have found improvements in urge incontinence symptoms and reductions in nocturnal voiding.

What Works for Stress Incontinence

Pelvic floor muscle training (PFMT) has the strongest evidence base for SUI. Meta-analyses consistently show that supervised PFMT reduces leakage frequency, volume, and bother more effectively than no treatment.[5] The training involves repeatedly contracting and relaxing the pelvic floor muscles in progressively challenging protocols.

Three things determine effectiveness: - Supervised training with a pelvic health physiotherapist produces better results than unsupervised exercises - Results require consistency over at least 3 months - Many women inadvertently contract abdominal or buttock muscles instead; correct targeting matters

For SUI that does not respond to conservative management, surgical options (mid-urethral sling procedures) have strong evidence for effectiveness.

What Works for Urge Incontinence

For UUI, treatment targets the overactive detrusor. First-line approaches are behavioural.

Bladder training involves gradually extending time between voids and using suppression techniques (pelvic floor contractions, distraction) when urgency arises. The goal is retraining bladder capacity and reducing the urgency response. Studies show reductions in urgency episodes with consistent bladder training.

Local vaginal estrogen reduces urgency and frequency in women with postmenopausal UUI, with effects typically apparent within 6–12 weeks of regular use.[4]

Anticholinergic and beta-3 agonist medications (oxybutynin, solifenacin, mirabegron) reduce detrusor overactivity pharmacologically. They are effective but carry side effect profiles (dry mouth, constipation, and cognitive effects in older women for anticholinergics particularly) that affect tolerability.

Starting the Clinical Conversation

Given prevalence and the range of effective treatments available, urinary incontinence in menopause warrants a clinical conversation. Whether leakage occurs with activity, with urgency, or both determines which treatment pathway is appropriate.

Questions worth raising with a GP or continence specialist: - Which type of incontinence is dominant? - Is a referral to a pelvic health physiotherapist appropriate? - Would local vaginal estrogen be appropriate alongside or instead of other treatment?

References

[1] Li, Y., et al. (2024). The link between menopause and urinary incontinence: a systematic review. Frontiers in Medicine. https://pmc.ncbi.nlm.nih.gov/articles/PMC11550778/

[2] Robinson, D., Cardozo, L. (2003). The role of estrogens in female lower urinary tract dysfunction. Urology, 62(4 Suppl 1), 45-51. See also: Local oestrogen for pelvic floor disorders: a systematic review. https://pmc.ncbi.nlm.nih.gov/articles/PMC4575150/

[3] Hendrix, S. L., Cochrane, B. B., Nygaard, I. E., et al. (2005). Effects of estrogen with and without progestin on urinary incontinence. JAMA, 293(8), 935-948. https://doi.org/10.1001/jama.293.8.935

[4] Rahn, D. D., Ward, R. M., Sanses, T. V., et al. (2015). Vaginal estrogen use in postmenopausal women with pelvic floor disorders: systematic review and practice guidelines. International Urogynecology Journal, 26(1). See also: Local oestrogen for pelvic floor disorders. https://pmc.ncbi.nlm.nih.gov/articles/PMC4575150/

[5] Dumoulin, C., Cacciari, L. P., Hay-Smith, E. J. C. (2018). Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women. Cochrane Database of Systematic Reviews, 10, CD005654. https://doi.org/10.1002/14651858.CD005654.pub4